Abstract
BackgroundHere we report the efficacy and safety of the Phase (Ph)3 LUCENT-2 study, a double-blind, randomized withdrawal maintenance study, in patients who responded to mirikizumab (miri) induction therapy.MethodsMiri induction clinical...
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have